Human Genome Sciences Inc. (Nasdaq: HGSI) announced positive results for its drug candidate in reducing symptoms of lupus. The stock price climbed 52 points to $3.23.
Search
About this Entry
This page contains a single entry by published on June 11, 2009 10:41 AM.